| Product Unit Size | Cost | Quantity | Stock |
|---|
Rifaximin is a rifampicin derivative with weaker absorption kinetics; it inhibits DNA-dependent RNA polymerase. Rifaximin is an ansamycin antibacterial compound that is clinically used to treat small intestinal bacterial overgrowth in subjects with inflammatory bowel syndrome (IBS).
| Cas No. | 80621-81-4 |
|---|---|
| Purity | ≥98% |
| Formula | C43H51N3O11 |
| Formula Wt. | 785.88 |
| Chemical Name | [2S-(2R*,16Z,18E,20R*,21R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7- [epoxypentadeca(1,11,13)trienimino]-benzofuro[4,5-e]- pyridol[1,2-a]benzimidazole-1,15(2H)-dione |
| Synonym | Rifacol, XIFAXAN, Fatroximin, Normix, Rifacol |
| Melting Point | 200-205°C (dec) |
| Solubility | Soluble in alcohols, ethyl acetate, chloroform or toluene. |
| Appearance | A Red Orange Powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Huhulescu S, Sagel U, Fiedler A, et al. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile. J Med Microbiol. 2011 Aug;60(Pt 8):1206-12. PMID: 21292853.
Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139-42. PMID: 18217406.